Rohan Garje

2.8k total citations · 1 hit paper
79 papers, 1.8k citations indexed

About

Rohan Garje is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Rohan Garje has authored 79 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 23 papers in Surgery. Recurrent topics in Rohan Garje's work include Prostate Cancer Treatment and Research (21 papers), Bladder and Urothelial Cancer Treatments (19 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Rohan Garje is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Bladder and Urothelial Cancer Treatments (19 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Rohan Garje collaborates with scholars based in United States, France and United Kingdom. Rohan Garje's co-authors include Raju Vaddepally, Abhinav Chandra, Prakash Kharel, Ramesh Kumar Pandey, Yousef Zakharia, Adithya Chennamadhavuni, Praveen Vikas, Nicholas Borcherding, Jeffrey M. Stolwijk and Laila Dahmoush and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rohan Garje

65 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

2020 895 citations Raju Vaddepally, Rohan Garje et al. Cancers profile →

Peers

Rohan Garje

ONCOL

PRM

IMMUN

Leyre Zubiri United States

Tom Wei‐Wu Chen Taiwan

Erika Rijavec Italy

Vladmir Cláudio Cordeiro de Lima Brazil

Nicola Battelli Italy

Cinzia Solinas Italy

Kyung Hwan Kim South Korea

Laura Pizzuti Italy

Yusuke Okuma Japan

Alex Friedlaender Switzerland

Leyre Zubiri United States

Rohan Garje

1.3k ×1.2

ONCOL

450 ×0.8

PRM

402 ×0.9

329 ×0.8

IMMUN

287 ×1.2

Citations per year, relative to Rohan Garje Rohan Garje (= 1×) peers Leyre Zubiri

Countries citing papers authored by Rohan Garje

Since Specialization

Citations

This map shows the geographic impact of Rohan Garje's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohan Garje with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohan Garje more than expected).

Fields of papers citing papers by Rohan Garje

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rohan Garje. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohan Garje. The network helps show where Rohan Garje may publish in the future.

Co-authorship network of co-authors of Rohan Garje

This figure shows the co-authorship network connecting the top 25 collaborators of Rohan Garje. A scholar is included among the top collaborators of Rohan Garje based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rohan Garje. Rohan Garje is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McKay, Rana R., Shayan Nazari, Andrew Elliott, et al.. (2025). Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer. The Oncologist. 30(11).

Garje, Rohan, Bernadett Szabados, Colleen Peyton, et al.. (2025). LBA112 Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results. Annals of Oncology. 36. S1652–S1653.

Rubens, Muni, et al.. (2025). Survival analysis comparing bladder preservation techniques in octogenarians with muscle-invasive bladder cancer. Translational Andrology and Urology. 14(2). 280–288.

Necchi, Andrea, Félix Guerrero‐Ramos, Paul L. Crispen, et al.. (2025). TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial. The Lancet Oncology. 26(10). 1312–1322.

Garje, Rohan, et al.. (2025). Signet ring cell carcinoma of the urachus: survival and pathologic outcomes from the national cancer database. International Urology and Nephrology.

Guerrero‐Ramos, Félix, Rohan Garje, Colleen Peyton, et al.. (2024). P262 TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy: interim analysis of SunRISe-4. European Urology Open Science. 69. 332–333. 1 indexed citations

Rubens, Muni, et al.. (2024). Pathological response and survival outcomes after neoadjuvant chemotherapy with radical cystectomy in octogenarians for muscle-invasive bladder cancer: an observational database study. BMC Urology. 24(1). 150–150.

Kyriakopoulos, Christos E., Yu‐Hui Chen, Robert Jeraj, et al.. (2024). Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).. Journal of Clinical Oncology. 42(17_suppl). LBA5000–LBA5000. 2 indexed citations

Ahmad, Shahzaib, et al.. (2024). Impact of delirium on in-patient outcomes in patients with pancreatic cancer: A nationwide study.. Journal of Clinical Oncology. 42(16_suppl). e16369–e16369. 1 indexed citations

10.

Zakharia, Yousef, Eric A. Singer, Rohan Garje, et al.. (2024). Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nature Communications. 15(1). 972–972. 6 indexed citations

11.

Guerrero‐Ramos, Félix, Rohan Garje, Tom Powles, et al.. (2024). LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4). Annals of Oncology. 35. S1271–S1272. 4 indexed citations

12.

Stewart, Tyler F., Sarah E. Fenton, Shayan Nazari, et al.. (2024). Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression.. Journal of Clinical Oncology. 42(16_suppl). 4585–4585. 1 indexed citations

13.

Vikas, Praveen, Hans Messersmith, Carolyn C. Compton, et al.. (2023). Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. Journal of Clinical Oncology. 41(10). 1943–1948. 57 indexed citations

14.

Vaddepally, Raju, et al.. (2022). Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge. Biomedicines. 10(4). 790–790. 34 indexed citations

15.

Garje, Rohan, et al.. (2022). Significant financial differences of chemical and surgical androgen deprivation in a contemporary cohort. Translational Andrology and Urology. 11(9). 1252–1261. 2 indexed citations

16.

Joshi, Monika, Sheldon L. Holder, Junjia Zhu, et al.. (2021). Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study. European Urology Focus. 8(2). 483–490. 6 indexed citations

17.

Garje, Rohan, et al.. (2020). Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer. The Oncologist. 25(11). e1711–e1719. 33 indexed citations

18.

Garje, Rohan, et al.. (2020). The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma. Cancers. 12(1). 143–143. 39 indexed citations

19.

Vikas, Praveen, Nicholas Borcherding, Adithya Chennamadhavuni, & Rohan Garje. (2020). Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. Frontiers in Oncology. 10. 570–570. 125 indexed citations

20.

Yadav, Meeta, Muhammad Furqan, Nathaniel C. Cady, et al.. (2019). OA03.04 Analysis of Patient Microbiome and Its Correlation to Immunotherapy Response and Toxicity in Lung Cancer. Journal of Thoracic Oncology. 14(11). S1132–S1132.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact